Organogenesis Holdings Stock
Organogenesis Holdings Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Gary S. Gillheeney
- Employees
- 854
- Market cap
- $129 M
- IPO
- 05/01/2017
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct…
Organogenesis Holdings stock: price history
1D
-9.9%
1W
-22.5%
1M
-28.1%
6M
-60.0%
YTD
-80.7%
1Y
-75.4%
2Y
-69.2%
5Y
-90.9%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~75% stronger price swings than usual
Ask the agents about Organogenesis Holdings
Analyst assessment of Organogenesis Holdings
PRICE TARGET LOW
US$2.00
CONSENSUS
US$2.50
MEDIAN
US$2.50
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
4
BUY
2
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 07/08/2026
Organogenesis Holdings stock metrics
P/E
-1.22
P/B
0.45
EV/EBITDA
-82.64
RETURN ON EQUITY
-34.5%
NET MARGIN
-227.0%
DEBT/EQUITY
0.23
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
47.5%
FLOAT SHARES
61,058,647
AVG. DAILY VOLUME (30D)
690,200
Institutional holders
Comparable stocks
Frequently asked questions about Organogenesis Holdings stock
What does Organogenesis Holdings do?
Organogenesis Holdings Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Gary S. Gillheeney, the company employs around 854 people.
The IPO was on 05/01/2017; the stock trades on NASDAQ under the ticker ORGO.
What do analysts say about Organogenesis Holdings stock?
6 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$2.50, ranging from US$2.00 to US$3.00, with a median of US$2.50.
This is an external assessment, not a statement by Market Jury.
When does Organogenesis Holdings report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 75% stronger than usual.
Does Organogenesis Holdings pay a dividend?
No, Organogenesis Holdings currently does not pay a dividend.
Which stocks are comparable to Organogenesis Holdings?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Organogenesis Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Organogenesis Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.